---
title: "Eye disease therapy developer EIR Biopharma files for a $17 million IPO"
description: "EIR Biopharma, a preclinical biotech focused on eye disease therapies, has filed for a $17 million IPO with the SEC. The San Francisco-based company plans to offer 3.8 million shares priced between $4"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276183035.md"
published_at: "2026-02-17T23:57:19.000Z"
---

# Eye disease therapy developer EIR Biopharma files for a $17 million IPO

> EIR Biopharma, a preclinical biotech focused on eye disease therapies, has filed for a $17 million IPO with the SEC. The San Francisco-based company plans to offer 3.8 million shares priced between $4 and $5. EIR Biopharma develops treatments for conditions like dry age-related macular degeneration and retinal nerve injury, with plans to start human clinical studies in 2027. Founded in 2022, the company aims to list on the NYSE American, with Kingswood Capital Markets as the sole bookrunner.

EIR Biopharma, a preclinical biotech developing in-licensed therapies for eye diseases, filed on Tuesday with the SEC to raise up to $17 million in an initial public offering.

The San Francisco, CA-based company plans to raise $17 million by offering 3.8 million shares at a price range of $4 to $5.

EIR Biopharma is an early-stage biopharmaceutical developer focused on treatments for eye diseases. It licenses preclinical drug candidates from academic institutions and advances them toward clinical development, targeting assets that address defined unmet needs. Its product candidates include EIR-0205, a small-molecule therapy in development for dry age-related macular degeneration (dry AMD) designed to extract lipofuscin from the retinal epithelium, and EIR-1003, a peptidomimetic candidate designed to mimic ephrin ligands and promote retinal nerve regeneration in optic nerve injury. The company is conducting IND-enabling activities for both programs and plans to initiate human clinical studies beginning in 2027.

EIR Biopharma was founded in 2022 and plans to list on the NYSE American, although it has not yet selected a symbol (RC: ticker: EIRB.RC). Kingswood Capital Markets is the sole bookrunner on the deal.

### Related Stocks

- [EIGRQ.US - EIGER BIOPHARMACEUTICALS INC](https://longbridge.com/en/quote/EIGRQ.US.md)
- [IHF.US - iShares US Healthcare Providers](https://longbridge.com/en/quote/IHF.US.md)
- [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md)
- [AMAM.US - Ambrx Biopharma](https://longbridge.com/en/quote/AMAM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 阿尔伯塔投资管理公司降低了其在联合健康集团公司 $UNH 的股票头寸 | 阿尔伯塔投资管理公司已大幅减少其在联合健康集团（NYSE: UNH）中的持股比例，降幅达到 98.8%，目前仅持有 900 股，此前在第三季度出售了 72,500 股。该公司的持股价值为 311,000 美元。其他投资者也在联合健康集团进行 | [Link](https://longbridge.com/en/news/276427903.md) |
| 恩赛因集团（NASDAQ:ENSG）董事 Pison Marivic Uychiat 出售 67 股股票 | Ensign Group（纳斯达克代码：ENSG）董事 Pison Marivic Uychiat 以每股 204.92 美元的价格出售了 67 股，总计 13,729.64 美元，导致其持股比例下降 0.47%。出售后，Uychiat 持 | [Link](https://longbridge.com/en/news/276498475.md) |
| 创纪录的 IPO 回归：为什么散户投资者可能正在走入陷阱 | 创纪录的首次公开募股回归：为什么散户投资者可能正走入陷阱 | [Link](https://longbridge.com/en/news/276539891.md) |
| Averin Capital 收购公司完成了首次公开募股 | Averin Capital Acquisition 完成首次公开募股（IPO） | [Link](https://longbridge.com/en/news/276488533.md) |
| 缅因州疾病控制与预防中心报告称，缅因州已确认新增 4 例麻疹病例 | 缅因州疾病控制中心报告缅因州新增 4 例麻疹确诊病例 | [Link](https://longbridge.com/en/news/276164223.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.